Asthma, COPD Disease Severity May Increase Risk of Developing Severe COVID-19
Disease severity of both chronic obstructive pulmonary disease (COPD) and asthma may increase the risk of the development of severe coronavirus disease 2019 (COVID-19).
Disease severity of both chronic obstructive pulmonary disease (COPD) and asthma may increase the risk of the development of severe coronavirus disease 2019 (COVID-19).
Compared with the absence of asthma, the presence of asthma is associated with a comparable risk of hospitalization and use of mechanical ventilation, and a lower risk of mortality in patients with COVID-19.
In patients with asthma, the use of inhaler electronic medication monitors with both rescue and controller inhalers is associated with higher adherence to these devices.
The majority of patients with asthma and nasal polyposis who were treated with benralizumab were considered “comprehensive responders.”
The incidence and prevalence of a first-ever spontaneous pneumothorax in patients with chronic obstructive pulmonary disease (COPD) and emphysema are increased significantly in men and in Black patients.
The use of regular, low-dose, oral sustained-release morphine for 4 weeks in patients with COPD and moderate to very severe breathlessness has been shown to improve disease-specific health status.
Both stable current smokers and individuals who had quit exhibited significantly less anxiety but more depression.
In patients with COPD, tiotropium/olodaterol was associated with a lower risk for escalation to triple therapy or the development of adverse outcomes compared with LABA/ICS.
High plasma omega-3 polyunsaturated fatty acid levels have been shown to be associated with a slower progression of percent emphysema.
Patients with asthma-chronic obstructive pulmonary disease overlap may have an increased independent risk for lung cancer that is similar to those with COPD, but higher than smokers with asthma and normal spirometry values.